Portage Buys Tarus, Gaining Cancer Assets Targeting Immune Evasion

Acquisition valued at roughly $21m upfront for two clinical and two preclinical adenosine receptor antagonists.

magnet
Portage picked up Tarus in a stock-based acquisition. • Source: Shutterstock

Portage Biotech Inc.will expand its clinical stage immuno-oncology pipeline with the addition of two adenosine receptor antagonists through the acquisition of Tarus Therapeutics. Publicly traded Portage, a company led by former immuno-oncology specialists who previously worked at Bristol Myers Squibb Company, will buy privately held Tarus in a stock transaction valued at around $21m upfront.

Tarus investors will also be able eligible to receive up to $32m in potential future development and sales milestone payments...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

Lupin’s Cimzia Biosimilar Candidate Reflects Strategy To Separate Wheat From Chaff

 
• By 

Lupin's choice of a Cimzia biosimilar candidate and partnering with Zentiva reflect a strategy to sort the wheat from the chaff. Of 118 biologics to lose patent protection between 2025 and 2034 as per IQVIA, it’s going for a biosimilar with a single competitor though there could be other spoilers

Merck & Co.’s Verona Acquisition Marks A Return To Respiratory

 

With the $10bn acquisition of Verona, Merck gains the marketed COPD drug Ohtuvayre, reentering respiratory, where it was once a leader with Singulair.

BREAKING NEWS: Merck & Co. Leaps Into COPD Space With $10bn Verona Buy

 
• By 

The UK firm's chronic obstructive pulmonary drug Ohtuvayre has been enjoying a stellar launch.

Wave of Biopharma Licensing Deals in India: ‘The Model Is Working’

 

From vonoprazan and inclisiran to nirsevimab, big pharma has licensed several products to Indian firms as have other biopharma players. Experts discuss the intricacies of such licensing deals amid signs of more action in store and whether geopolitics could dull partnering with Chinese firms.

More from Business